626 results about "Antigen specific" patented technology

In accordance with at least one aspect of this disclosure, there is provided an imaging agent, a including dye compound conjugated to an antigen specific targeting vector which can be particularly advantageous because their behavior in vivo can contribute to superior optical imaging properties, for example, by significantly increasing the target-to-background ratio of imaged tissues, leading to higher resolution imaging, and ultimately providing for better recognition of malignant tissue for resection and margin assessment and improved visualization during minimal invasive laparoscopic surgery, for example. A method of imaging tumor cells in a subject, can include, administering an imaging effective amount of an imaging agent according at least one embodiment of the invention; 2-4 hours after administration of the imaging agent, irradiating a region in the subject in which tumor cells are expected to be found with at a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent, thereby imaging the tumor cells, wherein the target-to-background ratio 2-4 hours after administration is from about 2.75 to about 15.

The invention relates to a detection kit for epithelial-mesenchymal transition in EB virus infected thymoma and application, the detection kit comprises a quantum dot labeled antibody E-Cadherin and a quantum dot labeled antibody Vimentin, a quantum dot is coupled with a specific antibody, a thymoma paraffin section sample is dyed through the quantum dot and the specific antibody conjugate, and the EB virus infected thymoma is obtained. The conjugate can be specifically connected with an EMT related antigen expressed in the slice, so that the quantum dots can be used for qualitative or quantitative detection of the EMT-generated thymoma cells. The quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of epithelial cells and mesenchymal tissues in the thymoma microenvironment is achieved, number detection and position detection can be achieved, and EMT condition evaluation is facilitated.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The invention belongs to the technical field of vaccines and biology, and particularly relates to a broad-spectrum influenza A vaccine immunogen composition and application. The invention provides a nucleic acid molecule for coding an immunogenic peptide, wherein the immunogenic peptide comprises: M2 protein extracellular region (M2e) peptide fragments which are connected in series; a hemagglutinin protein stem region extracellular domain (HA2) peptide fragment derived from an H7N9 influenza virus subtype; multimerization of the motif peptide fragment; and optionally, one or more linker peptide fragments independently located between the peptide fragments, wherein the polynucleotide molecule comprises a coding nucleic acid of each peptide fragment. The broad-spectrum influenza A vaccine can induce an organism to generate antigen-specific immune response, a high-titer antibody can be generated 14 days after last inoculation, the broad-spectrum influenza A vaccine can completely protect and resist attack of various subtype influenza A viruses, and the broad-spectrum influenza A vaccine has a wide application prospect.

The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

The invention belongs to the technical field of molecular biology and immunology, and provides an alpaca-derived nano antibody specifically bound with a simian vacuolar virus 40 large T antigen SV40LTA and application of the alpaca-derived nano antibody. The invention relates to a heavy chain antibody, which has a heavy chain variable region VHH, the VHH comprises the following CDR: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3, the VHH comprises four frame regions of FR1-4, and FR1, FR2, FR3 and FR4 and CDR1, CDR2 and CDR3 are arranged in a staggered manner in sequence. The antibody is high in neutralizing activity and strong in binding capacity with SV40LTA, and the equilibrium dissociation constant is less than 0.1 nM; the monoclonal antibody has the advantages that the monoclonal antibody can effectively recognize SV40LTA, the molecular weight is small, the immunogenicity is small, the solubility and stability are better, and the CDR region is longer; and a potential application value is provided for SV40LTA detection.

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or receptor thereof.

The invention relates to the technical field of biological pharmacy, in particular to a novel vaccine delivery system. According to the vaccine delivery system, lymph node co-delivery of the antigen and the adjuvant can be achieved, the immunity promoting effect of the adjuvant is effectively enhanced, the specific immune response of the antigen is remarkably improved, and the vaccine delivery system is superior to a clinically common oil type composite adjuvant system. Particularly, the vaccine delivery system shows a remarkable anti-tumor effect in tumor prevention and treatment, and a new thought is provided for development and application of a novel vaccine system.

The invention provides a method for detecting an external vesicle marker through high-flux nano plasma exciting light immune color development, and belongs to the technical field of human extracellular vesicles. After a serum sample is subjected to centrifugal treatment, the serum sample and a CD81 capture antibody substrate are incubated, and the particle size distribution of the vesicles is monitored in real time; a zwitterionic polymer modified gold nanoparticle LAM detection probe and a polyethylene glycol modified silver nanoparticle LprG detection probe are prepared to be specifically combined with a vesicle surface antigen, a chromogenic enhancement solution is adopted to induce a plasma resonance signal, and full-hole scanning imaging is carried out; and constructing a double-layer game optimization model to cooperatively optimize the detection sensitivity and the signal stability, carrying out weighted summation on normalized signals of the particle size subgroups to obtain comprehensive detection signal intensity, comparing the comprehensive detection signal intensity with a threshold value, and outputting a final judgment result. The technical problem that quantitative accuracy is affected by signal intensity deviation caused by vesicle particle size difference in outer vesicle marker detection is solved.

The invention relates to a method for detecting Breg cells and Tfh cells in a chest adenoma tissue microenvironment, which comprises the following steps of: coupling quantum dots with a specific antibody, dyeing a chest adenoma tissue slice sample, and specifically connecting the specific antibody with antigens on the Breg cells and / or Tfh cells in the slice sample cells, so as to quantify or position the Breg cells and / or Tfh cells by the quantum dots. According to the method disclosed by the invention, the existing multicolor immunofluorescence technology is improved, and a secondary antibody dyeing link is omitted by using a method of carrying the antibody by the quantum dots, so that the efficiency is improved; the quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of Breg cells and Tfh cells in a thymoma tumor microenvironment is achieved, and biological behaviors of the Breg cells and the Tfh cells can be determined conveniently; the immune condition can be evaluated by detecting the ratio condition of Breg / Tfh cells in the breast adenoma tumor microenvironment of a patient in vitro.

Transgenic rodents and rodent cells that express components of the human immune system, and their uses in generating human T cell receptors (TCRs). A genetically modified rodent comprising a TCR alpha gene locus comprising unrearranged human TCR alpha variable gene segments and a human TCR alpha constant region, and a TCR beta gene locus comprising unrearranged human TCR beta variable gene segments and a human TCR beta constant region. Use of hTCR transgenic rodents to generate antigen-specific CD8+ T cell responses for the discovery of fully human TCR sequences with therapeutic potential.

The present disclosure relates to fusion immunocytokines comprising antibodies or antigen binding fragments specific for immune cell associated antigens, such as PD-1, and IL- 18 polypeptides. Also provided herein are methods of treatment with and methods of manufacture of such fusion immunocytokines.

The present invention relates to a loadable, multivalent virus-like particle (VLP) system which presents a multitude of MHC-I molecules comprising different allotype and antigen specificities, and methods for mating and using the same.

The invention belongs to the field of biomedical detection, and particularly relates to a protein chip, a detection kit based on a polypeptide coding microarray chip and application of the detection kit. According to the protein chip provided by the invention, an antibody and a bispecific antibody of corresponding indexes can be added into a treating fluid according to detection requirements, the antibody and the bispecific antibody are combined with the chip in a manner of polypeptide specific recognition after being subjected to antigen specific recognition respectively, and joint detection of different antigen combinations and detection of a single index are carried out. By utilizing the polypeptide sample application chip and the antigen and antibody combined bispecific antibody provided by the invention, the universality of the chip in use, the high efficiency of detection and the low cost can be remarkably improved.

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a universal whole-pig monoclonal antibody. The present invention is based on single B cell antibody preparation technology, and antigen-specific single B lymphocytes are separated from the peripheral blood of immune pigs or clinically recovered pigs by flow cytometry sorting technology; according to the pig immunoglobulin IgG antibody gene sequence in the database, primers are designed to specifically amplify the complete coding genes of antibody heavy and light chains in pig single B cells and add His tags, and pCDNA3.1-Leader is used as a eukaryotic expression vector to construct a recombinant vector of complete coding genes for antibody light and heavy chains, and natural whole-pig monoclonal antibodies are expressed by mammalian cells. The present invention establishes a universal whole-pig monoclonal antibody preparation method for the first time, which can be used for the preparation and screening of pig monoclonal antibody libraries of different pathogens. Compared with other antibody preparation methods, it has the advantages of high throughput, whole pig source, good diversity, complete antibodies and natural pairing, etc., which provides technical support for the rapid preparation and screening of pig monoclonal antibodies and has broad application prospects.

The present disclosure provides recombinantly manufactured fusion proteins comprising a Programmed Death-Ligand 1 (PD-L1) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients as a treatment for cancers, tumors or other diseases associated with expression of the PD-L1 protein in dogs. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids, and the method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids comprises the following steps: after separating PBMC, enriching CD8 + T cells, and stimulating the CD8 + T cells by using DC loaded with candidate neoantigen polypeptide to obtain neoantigen specific CTL; new antigen-specific CTL is tested through the kit, secretion of IFN-gamma is detected, and antigen-specific CTL with positive reaction is screened out; the method comprises the following steps: selecting a candidate new antigen capable of specifically stimulating CTL to generate an IFN-gamma positive reaction according to an experiment result of secreting IFN-gamma by the CTL, establishing a tumor organoid-CTL cell co-culture system, setting PBMC primary T cells of a patient which are not stimulated by DC loaded with the candidate new antigen as a control group, and measuring organoid light microscope radiography and tumor cell death conditions. The function of the sarcoma high-frequency neoantigen is evaluated based on tumor organs.

The invention discloses a method for quantitatively detecting the specific activity of a MntC antigen in a recombinant staphylococcus aureus vaccine or / and a stock solution. The method comprises the following steps: (1) coating an elisa plate by taking MntC-686 as a capture antibody; (2) adding a sample to be detected into the coated ELISA plate; (3) carrying out a chromogenic reaction by using HRP-MntC-A7, and measuring an OD450 / 630 nm value; and (4) preparing a standard curve by using the MntC reference, and calculating the specific activity of the MntC antigen in the detected sample according to the standard curve. According to the present invention, the fully human monoclonal antibody for specifically recognizing the recombinant staphylococcus aureus vaccine MntC protein is adopted as the coating antibody, and the anti-MntC protein fully human monoclonal antibody is adopted as the detection antibody; the kit can be used for detecting the specificity of the MntC antigen in a staphylococcus aureus vaccine or a stock solution, and has good stability and repeatability.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Provided herein are methods for preparing and characterizing SARS-co2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections and immune disorders. Also, provided are compositions and methods for generating immune cells expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARs-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

The present invention relates to a composition comprising physiological dendritic cells and at least one mRNA. The invention further relates to a composition comprising physiological dendritic cells and at least one mRNA for vaccination.

The present invention provides compositions and methods for inducing antigen-specific tolerance in a subject. In one embodiment, the present invention provides a composition comprising an apoptotic body and an epitope of an antigen. Also provided herein are methods of preparing and administering the composition. The composition and methods provided herein can induce antigen-specific tolerance in a subject.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention relates to an application of a macrophage expressing an anti-uPAR chimeric antigen receptor in preparation of an anti-aging drug, and discloses a new application of the macrophage (CAR-M) expressing the anti-uPAR chimeric antigen receptor in senescence diseases, and the mechanism is that uPAR positive cells are specifically recognized and apoptosis of the uPAR positive cells is induced by targeting senescence cell surface antigen uPAR. According to the uPAR-CAR-M, a humanized anti-uPAR single-chain antibody is used as a chimeric antigen receptor recognition region, so that the chimeric antigen receptor has high specificity, and the chimeric antigen receptor is used for promoting the functions of macrophages by using a CD8 alpha transmembrane structural domain, a CD28 costimulatory molecule and a Megf10 sequence, so that a better killing effect is given to the CAR-M. The problems of inflammatory microenvironment caused by abnormal aggregation of senescence cells, chronic tissue damage and senescence-related disease treatment disorder are solved, and the application value for treating senescence-related diseases (such as osteoarthritis and the like) expressing uPAR is important.

Aspects of the present disclosure include methods and compositions related to therapeutic immune cells having enhanced metabolic fitness. In certain aspects, polynucleotides encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism and, optionally, one or more antigen-specific receptors, are disclosed. In some aspects, disclosed are methods for enhancing the metabolic fitness of an immune cell comprising introducing into the immune cell a polynucleotide encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism. Cells (e.g., NK cells, T cells) expressing polynucleotides encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism and, optionally, one or more antigen-specific receptors are described. Also described are therapeutic methods using polynucleotides of the disclosure.

The invention provides an mRNA (messenger Ribonucleic Acid) or mRNA-LNP (Leucine Natriuretic Peptide) compound for coding antibody-antigen fusion protein and application thereof, and belongs to the technical field of cell therapy. Wherein the coding frame sequence of the mRNA comprises an antibody sequence, a cleavage sequence and an antigen peptide sequence; wherein the antibody targets a tumor high-expression surface protein, and the antigen is a high-immunogenicity antigen. According to the mRNA-coded antibody-antigen fusion protein, high-expression protein on the surface of a tumor cell is specifically recognized through an antibody, and a high-immunogenicity antigen is introduced into a recognized tumor target cell to mark the tumor cell. The mRNA can be ingested, processed and presented by antigen presenting cells so as to stimulate and activate antigen-specific TCR-T cells in vivo. Therefore, the widely labeled tumor cells can be specifically recognized and killed by the antigen-specific TCR-T cells in vivo.

The present application is directed, in general, to compositions comprising antigens and cGAS-STING pathway activating agents and uses thereof to induce or enhance tolerogenic immune responses to an antigen.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The invention belongs to the technical field of medicines, and discloses a mycobacterium tuberculosis fusion protein LT57 construction and expression purification method, a mycobacterium tuberculosis cell wall antigen Rv0518 and mycobacterium tuberculosis PE / PPE family antigens PE25 and PPE41 are fused, and the fusion protein PE25-linker-PPE41-Rv0518 is constructed by connecting the fusion protein Rv0518 and the fusion protein PPE41 through flexible peptide fragments. The fusion protein is expressed in a prokaryotic expression vector E.coli BL21 (DE3), and is obtained through column chromatography purification. The fusion protein LT57 and an adjuvant DP are combined to construct a tuberculosis subunit vaccine, a relatively strong specific cellular immune response aiming at a specific antigen of mycobacterium tuberculosis can be induced in a mouse body, the long-term generation of memory T cells is promoted, and the tuberculosis subunit vaccine has relatively strong immunogenicity. The novel fusion protein LT57 is successfully constructed, expressed and purified, and antigen-specific cellular immunity and humoral immunity can be induced.